Cellectar Biosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details)								1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
STOCKHOLDERS' EQUITY (Details)	Jun. 24, 2025	Jun. 23, 2025	Jun. 10, 2025	Jun. 06, 2025 USD ($) $ / shares shares	Jul. 21, 2024 USD ($) D $ / shares shares	Sep. 08, 2023 USD ($) D $ / shares shares	Oct. 25, 2022 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2024 USD ($) shares	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Dec. 31, 2024 USD ($) shares	Oct. 31, 2022 shares
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares									522,008			522,008
Reverse stock split ratio	0.033		0.033
Net proceeds from warrant exercises \| $												$ 2,251,380	$ 43,849,468
Warrant liability \| $									$ 1,095,926			$ 1,095,926		$ 1,718,000
Preferred stock, share outstanding									35.6			35.6		35.60
Exercise of warrants for common stock \| $									$ 2,714,140		$ 2,298,143
Number of warrants exercised														18,239
September 2023 Private Placement
STOCKHOLDERS' EQUITY
Gross proceeds \| $						$ 24,500,000
Net proceeds \| $						$ 22,200,000
October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares							109,171
Exercise price of warrants (in dollars per share) \| $ / shares							$ 62.55
Proceeds from exercise of warrants \| $														$ 1,100,000
Gross proceeds \| $							$ 10,700,000
Estimated offering expenses \| $							$ 9,600,000
Common Stock
STOCKHOLDERS' EQUITY
Exercise of warrants for common stock (in shares)									276,044		18,239
Exercise of warrants for common stock \| $									$ 3
Common Stock \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares							62,531
Exercise price of warrants (in dollars per share) \| $ / shares							$ 58.8
Minimum
STOCKHOLDERS' EQUITY
Reverse stock split ratio		0.10
Maximum
STOCKHOLDERS' EQUITY
Reverse stock split ratio		0.033
Series E Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Share price \| $ / shares						$ 20,000
Series E-1 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares						$ 54.6
Shares issued						1,225
Convertible preferred shares issued						448,717
Gross proceeds from stockholders' equity \| $						$ 17,820,000
Series E-2 Preferred Stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares						$ 54.60
Conversion of preferred shares into common shares (in shares)														284.16
Convertible preferred shares issued						448,717
Preferred stock, share outstanding									35.6			35.6
Series E-2 Preferred Stock \| Common Stock
STOCKHOLDERS' EQUITY
Conversion of preferred shares into common shares (in shares)											30,132
Series E-2 Preferred Stock \| Common Stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion of preferred shares into common shares (in shares)														104,087
Series E-3 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares						$ 95.55		$ 95.55
Convertible preferred shares issued						461,538
Series E-3 preferred stock \| Common Stock
STOCKHOLDERS' EQUITY
Conversion of preferred shares into common shares (in shares)										89,482	329,670	461,538
Series E-4 preferred stock
STOCKHOLDERS' EQUITY
Fair value of the warrants allocated to preferred stock \| $					$ 15,900,000
Series E-4 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Conversion price per share \| $ / shares						$ 143.325
Convertible preferred shares issued						239,316
Series E-4 preferred stock \| Common Stock
STOCKHOLDERS' EQUITY
Conversion of preferred shares into common shares (in shares)														224,663
Tranche A and B Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Gross proceeds from stockholders' equity \| $						$ 4,800,000
Existing Warrant
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares				276,044
Exercise price of warrants (in dollars per share) \| $ / shares				$ 9.123
Proceeds from exercise of warrants \| $				$ 2,500,000
July 2024 Warrants
STOCKHOLDERS' EQUITY
Warrant liability \| $					12,000,000				$ 830,000			$ 830,000		$ 1,200,000
Fair value of warrants \| $					17,000,000
Prefunded Warrant \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares							62,531
pre-funded warrants														35,971
Tranche A Warrants \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Warrants term								10 days
Tranche A Warrants \| Series E-3 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Proceeds from exercise of warrants \| $								$ 44,100,000
Exercise of warrants for common stock (in shares)								2,205
Exercise of warrants for common stock \| $								$ 42,800,000
2023 Tranche A Preferred Warrants \| Series E-3 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares						2,205
Proceeds from exercise of warrants \| $						$ 44,100,000
Number of days \| D						10
2023 Tranche B Preferred Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares									14,652			14,652
Exercise price of warrants (in dollars per share) \| $ / shares									$ 143.25			$ 143.25
Exercise or Settlement of warrants \| $					$ 2,600,000
2023 Tranche B Preferred Warrants \| Series E-4 preferred stock
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares					1,610
Proceeds from exercise of warrants \| $					$ 19,400,000
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.00001
Number of shares issuable upon conversion of preferred stock					224,663
Conversion price per share \| $ / shares					$ 75.6
Net proceeds from warrant exercises \| $					$ 17,500,000
2023 Tranche B Preferred Warrants \| Series E-4 preferred stock \| September 2023 Private Placement
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares						1,715
Proceeds from exercise of warrants \| $						$ 34,300,000
Number of days \| D						10
2022 Pre-Funded Common Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares															62,531
2022 Pre-Funded Common Warrants \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Exercise price of warrants (in dollars per share) \| $ / shares							$ 0.00001
Purchase price \| $ / shares							$ 62.5497
2024 Tranche A Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares									158,728			158,728
Exercise price of warrants (in dollars per share) \| $ / shares					$ 75.6				$ 75.6			$ 75.6
Number of Days following the Announcement of Prescription Drug Use Fee Act Goal By FDA \| D					10
2024 Tranche B Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares									149,107			149,107
Exercise price of warrants (in dollars per share) \| $ / shares					$ 120				$ 120			$ 120
Number of days following the date of the Company's public announcement of its receipt of written approval from the FDA \| D					10
2024 Tranche C Warrants
STOCKHOLDERS' EQUITY
Warrants issued to purchase shares									75,912			75,912
Exercise price of warrants (in dollars per share) \| $ / shares					$ 165				$ 165			$ 165
Number of days following the announcement of quarterly gross revenue from sales of iopofosine I 131. \| D					10
Threshold amount of quarterly gross revenues trigger for expiry of warrants \| $					$ 10,000,000
Common Stock \| October 2022 Public Offering and Private Placement
STOCKHOLDERS' EQUITY
Conversion of preferred shares into common shares (in shares)														35,971